GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating GeneDx Holdings Corp. on Behalf of Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against GeneDx Holdings Corp. for possible violations of federal securities laws and unlawful business practices [1][3] Group 1: Allegations Against GeneDx - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to inflate revenue [3] - The report alleges that GeneDx has engaged in "code stacking," allowing the company to bill insurance providers for services that do not meet required criteria [3] - It is noted that CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, suggesting insider knowledge of imminent risks [3] Group 2: Stock Price Impact - Following the allegations, GeneDx's stock price fell by $4.84 per share, or 6.72%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Legal Options for Investors - Bragar Eagel & Squire encourages investors who suffered losses in GeneDx to contact them to discuss their legal rights and options [1][4]